image
Healthcare - Medical - Devices - NASDAQ - US
$ 6.11
-3.04 %
$ 162 M
Market Cap
-2.63
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RCEL stock under the worst case scenario is HIDDEN Compared to the current market price of 6.11 USD, AVITA Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RCEL stock under the base case scenario is HIDDEN Compared to the current market price of 6.11 USD, AVITA Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RCEL stock under the best case scenario is HIDDEN Compared to the current market price of 6.11 USD, AVITA Medical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RCEL

image
$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
64.3 M REVENUE
28.14%
-56.6 M OPERATING INCOME
-32.68%
-61.8 M NET INCOME
-74.80%
-48.9 M OPERATING CASH FLOW
-28.75%
37.4 M INVESTING CASH FLOW
2225.02%
3.51 M FINANCING CASH FLOW
-91.31%
18.4 M REVENUE
-5.83%
-9.96 M OPERATING INCOME
27.88%
-11.6 M NET INCOME
28.49%
-8.08 M OPERATING CASH FLOW
-12.02%
2.47 M INVESTING CASH FLOW
-66.58%
1.02 M FINANCING CASH FLOW
1.39%
Balance Sheet AVITA Medical, Inc.
image
Current Assets 57 M
Cash & Short-Term Investments 35.9 M
Receivables 12 M
Other Current Assets 9.15 M
Non-Current Assets 22.7 M
Long-Term Investments 0
PP&E 13.6 M
Other Non-Current Assets 9.12 M
45.02 %15.01 %11.48 %17.05 %11.44 %Total Assets$79.7m
Current Liabilities 20.2 M
Accounts Payable 6.29 M
Short-Term Debt 900 K
Other Current Liabilities 13 M
Non-Current Liabilities 55.1 M
Long-Term Debt 45.1 M
Other Non-Current Liabilities 9.97 M
8.37 %17.24 %59.94 %13.25 %Total Liabilities$75.2m
EFFICIENCY
Earnings Waterfall AVITA Medical, Inc.
image
Revenue 64.3 M
Cost Of Revenue 9.09 M
Gross Profit 55.2 M
Operating Expenses 112 M
Operating Income -56.6 M
Other Expenses 5.25 M
Net Income -61.8 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)64m(9m)55m(112m)(57m)(5m)(62m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
85.85% GROSS MARGIN
85.85%
-88.08% OPERATING MARGIN
-88.08%
-96.26% NET MARGIN
-96.26%
-1374.64% ROE
-1374.64%
-77.59% ROA
-77.59%
-93.70% ROIC
-93.70%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AVITA Medical, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -61.8 M
Depreciation & Amortization 1.13 M
Capital Expenditures -9.33 M
Stock-Based Compensation 13.5 M
Change in Working Capital -4.68 M
Others -2.54 M
Free Cash Flow -58.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AVITA Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for RCEL of $14 , with forecasts ranging from a low of $14 to a high of $14 .
RCEL Lowest Price Target Wall Street Target
14 USD 129.13%
RCEL Average Price Target Wall Street Target
14 USD 129.13%
RCEL Highest Price Target Wall Street Target
14 USD 129.13%
Price
Max Price Target
Min Price Target
Average Price Target
1515141413131212111110109988776655Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership AVITA Medical, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
212 K USD 2
3-6 MONTHS
18.5 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards. globenewswire.com - 2 weeks ago
AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
AVITA Medical Reports First Quarter 2025 Financial Results VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
AVITA Medical to Announce First Quarter 2025 Financial Results VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. globenewswire.com - 2 months ago
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. globenewswire.com - 2 months ago
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. globenewswire.com - 2 months ago
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm. globenewswire.com - 3 months ago
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference AVITA Medical announced that Jim Corbett, CEO, will present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. Eastern Time. globenewswire.com - 3 months ago
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 3 months ago
After Sales Rebound In January, AVITA Is Set Up For A Monster Year After Sales Rebound In January, AVITA Is Set Up For A Monster Year seekingalpha.com - 3 months ago
AVITA Medical to Host Investor Webinar Briefing AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT. globenewswire.com - 4 months ago
AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 4 months ago
8. Profile Summary

AVITA Medical, Inc. RCEL

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 162 M
Dividend Yield 0.00%
Description AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Contact 28159 Avenue Stanford, Valencia, CA, 91355 https://www.avitamedical.com
IPO Date May 14, 2012
Employees 260
Officers Mr. James M. Corbett Chief Executive Officer, President & Executive Director Dr. Niraj Doshi J.D., P.M.P., Ph.D. Senior Vice President of Product Development & Program Management Ms. Jessica Ekeberg Director of Investor Relations Mr. Ron Lagerquist Senior Vice President of Quality Assurance & Regulatory Affairs Mr. David O'Toole Chief Financial Officer Ms. Debbie Garner Senior Vice President of Global Marketing & Strategy Mr. Rob Hall Senior Vice President of Human Resources David Melbye Senior Vice President of Operations Dr. Katie Bush Ph.D. Senior Vice President of Scientific & Medical Affairs Ms. Nicole Linda Kelsey Chief Legal & Compliance Officer and Corporate Secretary